Glucotrack, Inc.

Glucotrack, Inc. is a U.S.-based medical device developer focused on novel diabetes technologies. Its core program is the Glucotrack CBGM, an implantable continuous blood glucose monitor being developed for people with Type 1 diabetes and insulin-dependent Type 2 diabetes.

1.61

— Glucotrack, Inc.
	%
Implantable glucose monitoring devices	0% The Glucotrack CBGM and related implantable continuous blood glucose monitoring technology for diabetes care.
Clinical development services	0% Clinical trial execution, testing, and development activities needed to advance the device toward commercialization.
Regulatory and FDA readiness	0% Work supporting FDA registration, documentation, and product approval preparation.
R&D and product engineering	100% Internal research, design, and engineering for new CBGM models and product candidates.

Glucotrack does not yet appear to have commercial customers because the CBGM has not been commercialized...

Type 1 diabetes patientsprimary
Future end users of the implantable CBGM who need continuous glucose data for insulin management.
Insulin-dependent Type 2 diabetes patientsprimary
Future end users who may benefit from continuous monitoring to improve glycemic control.
Clinical and regulatory stakeholderssecondary
Hospitals, investigators, and regulators involved in trials, validation, and FDA registration.
Capital providersprimary
Equity and debt investors funding development before commercialization.

Glucotrack is headquartered in the United States and its filings are on a U.S. reporting basis...

•Headquartered in the United States
•U.S. regulatory pathway is central to commercialization
•Clinical and R&D activity appears U.S.-based
•No disclosed country revenue mix because product is pre-commercial
•Future expansion depends on approval and market access

The company’s strategy is to advance the Glucotrack CBGM through clinical development, FDA registration, and eventual...

Clinical development of Glucotrack CBGMshort-term

Clinical evidence is required to support regulatory approval and future adoption.

FDA registration and regulatory progressshort-term

Regulatory clearance is the gate to commercialization and revenue generation.

Capital raising and liquidity preservationshort-term

The company is a going concern and needs external funding to continue operations.

Glucotrack faces classic pre-commercial medtech risks: it has not yet generated product revenue, needs significant...

critical

Going concern and liquidity shortfall

The company states current cash is not sufficient for the next twelve months and it needs external financing.

Scope: Operations, clinical trials, and product development
Materiality: high

high

Clinical and regulatory execution risk

Commercialization depends on successful trials and FDA registration, both of which can be delayed or fail.

Scope: Glucotrack CBGM development timeline
Materiality: high

high

Financing and dilution risk

The company plans to fund operations through debt or equity, which may be unavailable or dilutive.

Scope: Shareholders and capital structure
Materiality: high

medium

Commercial adoption risk

Even after approval, the implantable device must win physician and patient acceptance versus existing monitoring options.

Scope: Future revenue conversion
Materiality: medium

Derivative liabilities fair value

Can materially swing quarterly net loss

Stock-based compensation

Raises reported operating costs without cash outflow

Going concern estimates

Affects financial statement presentation and investor risk assessment

Convertible notes and warrant accounting

Can affect equity, liabilities, and financing expense

Glucotrack, Inc.

Going concern and liquidity shortfall

Clinical and regulatory execution risk

Financing and dilution risk

Commercial adoption risk

DEXCOM INC

ReposiTrak, Inc.

Structure Therapeutics Inc.

Vivani Medical, Inc.

BioCorRx Inc.

Modular Medical, Inc.